What is the management of early Huntington's disease (HD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the FDA Drug Label

The efficacy of tetrabenazine tablets as a treatment for the chorea of Huntington’s disease was established primarily in a randomized, double-blind, placebo-controlled multi-center trial (Study 1) conducted in ambulatory patients with a diagnosis of HD. Tetrabenazine tablets were started at a dose of 12.5 mg per day, followed by upward titration at weekly intervals, in 12.5 mg increments until satisfactory control of chorea was achieved, intolerable side effects occurred, or until a maximal dose of 100 mg per day was reached.

The management of early Huntington's disease (HD) with tetrabenazine tablets involves:

  • Starting with a dose of 12.5 mg per day
  • Upward titration at weekly intervals in 12.5 mg increments
  • Targeting a dose that achieves satisfactory control of chorea, but not exceeding 100 mg per day
  • Monitoring for side effects and adjusting the dose as needed 1

From the Research

The management of early Huntington's disease focuses on symptom control and supportive care, with a multidisciplinary approach involving neurologists, psychiatrists, genetic counselors, physical therapists, and social workers providing the most comprehensive care. For chorea, which is often the most visible symptom, tetrabenazine (12.5-25 mg three times daily) or deutetrabenazine (6-12 mg twice daily) are first-line medications, as supported by the most recent study 2. Antipsychotics like risperidone (0.5-2 mg daily) or olanzapine (2.5-10 mg daily) may help control both chorea and psychiatric symptoms. Depression can be treated with SSRIs such as sertraline (50-200 mg daily) or escitalopram (10-20 mg daily). Irritability and aggression might respond to mood stabilizers like valproate (250-500 mg twice daily).

Some key aspects of care include:

  • Physical therapy, occupational therapy, and speech therapy to maintain function as long as possible
  • Genetic counseling to understand inheritance patterns and reproductive options
  • Regular reassessment and adjustment of care plans to address changing symptoms and functional abilities
  • Early advance care planning discussions to establish the patient's wishes for future care

Alternative approaches, such as music therapy, video games, yoga, and exercise-based programs, may also have a role in improving symptoms, as discussed in a recent narrative review 2. However, the primary approach should remain focused on evidence-based symptom control and supportive care, with a multidisciplinary team guiding the management of the disease.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.